Advertisement
Singapore markets close in 4 hours 59 minutes
  • Straits Times Index

    3,169.77
    -17.89 (-0.56%)
     
  • Nikkei

    37,133.66
    -946.04 (-2.48%)
     
  • Hang Seng

    16,180.59
    -205.28 (-1.25%)
     
  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     
  • Bitcoin USD

    61,803.19
    -184.39 (-0.30%)
     
  • CMC Crypto 200

    1,277.85
    +392.31 (+42.68%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • Dow

    37,775.38
    +22.07 (+0.06%)
     
  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     
  • Gold

    2,404.20
    +6.20 (+0.26%)
     
  • Crude Oil

    84.98
    +2.25 (+2.72%)
     
  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     
  • FTSE Bursa Malaysia

    1,550.15
    +5.39 (+0.35%)
     
  • Jakarta Composite Index

    7,042.60
    -124.21 (-1.73%)
     
  • PSE Index

    6,413.88
    -109.31 (-1.68%)
     

Analyst Recommendations for Herbalife before 4Q17

Analyst Recommendations for Herbalife before 4Q17

Of the analysts covering Herbalife (HLF) stock, 50% of them are recommending a “buy,” and 50% are recommending a “hold.” Herbalife’s sales and profitability were subdued in the first three quarters of 2017. Herbalife’s financials are expected to remain challenged in the near term, given the weakness in its key regions. Currently, analysts have a price target of $86.80 per share for Herbalife stock, which represents an upside of 3.5% compared to its closing price of $83.88 on February 15, 2018.